Booking Holdings Inc (BKNG) Stock Price Today
Aura AI Summary
Key Stats
- $107.77BMarket Cap
- 7,679,027Volume
- Consumer CyclicalSector
- $219.6852W High
- $144.9152W Low
- 120 DaysTypical Hold Time
- $112.53BEnterprise Value
- 1.16%Div Yield
- 0% Sell | 100% BuyTrading Activity
Track Booking Holdings Inc (BKNG) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Booking Holdings Inc has traded between a low of $144.91 and a high of $219.68, highlighting its annual price range. Buy and sell Booking Holdings Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Booking Holdings Inc
Booking is the world's largest online travel agency by revenue, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates a number of branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.
Most Recent News
Home Depot and Lowe's see declining sales amid high mortgage rates and weak housing market.
Home Depot and Lowe's reported declines in comparable transactions in Q3 2026 due to a sluggish housing market and rising mortgage rates now above 7%. This has led to fewer home sales and softer demand for home improvement projects, as consumers dela...

Tesla's Cybercab launch signals robotaxi growth in 2027, urging caution on a SpaceX merger before success.
Tesla has started selling Cybercabs, priced at $29,990 with a $299 monthly subscription, but their current use is limited to specific areas and lacks manual controls. This launch is mainly promotional, highlighting Tesla's focus on becoming a transpo...

FDA approval for Grail's Galleri cancer test expected in early 2027, key for insurer coverage and pricing.
Grail expects FDA approval for its multi-cancer early detection test, Galleri, in Q1 2027, which could lead to Medicare and commercial insurer coverage. Despite a failed primary endpoint in a large NHS trial, Galleri showed promising results for 12 d...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.